Achilles Therapeutics (UK) is pushing the frontier of personalized adoptive T cell therapies. In the first round of the 2022 EIC Pathfinder program, an Achilles-led consortium was awarded €4 million from the “Emerging technologies in cell & gene therapy” Challenge, to develop a proof-of-concept, first-in-class, smart bioprocessing manufacturing platform. Image used with permission from Achilles…
Driven by the success of the hDMT (Institute for human organ and Disease Model Technologies) consortium, the new not-for-profit infrastructure, hDMT INFRA, is making microphysiological systems (MPS) technology available to users, and ready for (end-) user applications. This will facilitate and boost the adoption and implementation of real-world applications of MPS-based models. Catalyze supported hDMT…
LMNAcardiac.org is a new network for experts and patients focussed on LMNA cardiac diseases, with the aim of accelerating research and development to find effective treatments. The disease is caused by mutations in the LMNA gene, and is characterized by a high rate of major cardiac events caused by impaired contraction of the heart. Catalyze completed a…
Metriopharm’s ‘iMPact’ project was awarded a €7.9 million grant from the COVID-19 work programme from Horizon Europe, to clinically validate MP1032, an early intervention treatment against mild-to-moderate COVID-19. Catalyze provided support to Metriopharm for their successful application and now supports iMPact as a project partner, providing project management and dissemination services. We spoke with Dr….
VarmX is a spin-off from the Leiden University Medical Center (LUMC), on a mission to develop and manufacture therapeutic proteins that restore hemostasis in patients treated with anticoagulants. Catalyze recently supported their successful application for blended finance from the EIC Accelerator programme, to upscale and accelerate the manufacture of VarmX’s lead compound, VMX-C001. In October…
We met with Dr. Roy Kolkman, Manager of the Novel-T Knowledge Transfer Office (KTO) at the University of Twente to discuss the newly funded MedTech project, which was awarded €8 million from the Thematic Technology Transfer (TTT) scheme. The project was initiated by the 4TUs with UTwente as secretary. Catalyze’s Strategic Consultancy team provided support…
We met with Dr. Hanno Tan, cardiologist at the Amsterdam UMC, specialized in sudden cardiac arrest (SCA) and leading scientist in ESCAPE-NET, which aims to develop the first European network that aids to improve prevention and treatment of SCA. Catalyze successfully supported Dr. Tan’s initial application to Horizon 2020 and provide ongoing project management to…
Cardiovascular diseases remain the number 1 cause of death globally, being responsible for a staggering 31% of all deaths. Inge Sieben, CEO of Dutch start-up, Glanum Diagnostics, attempts to turn the tide by developing a novel small electrocardiogram patch for home monitoring. This innovation provides cardiac patients the ability to receive accurate measurements of their…
After working with Catalyze to secure a EU-Horizon 2020 grant for the ESCAPE-NET project, Dr. Hanno Tan returned to partner up again with Catalyze, this time winning funding from the European Cooperation in Science & Technology (COST) program. Catalyze provides ongoing project management support to the PARQ-COST project. We spoke with Dr. Tan about this…
The DEPREDICT project received a 3-year €2.3 million award from Eureka Eurostars, which supports consortium projects of up to 5 partners, led by an R&D performing SME. Read our interview with Marte Theuen, PhD, who was Project Coordinator of DEPREDICT for 1.5 years, until stepping down from her position as Chief Technology Officer at NordicNeuroLab…